Pharmaceutical Executive January 20, 2025
Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.
Pharmaceutical Executive: What’s causing the increase in M&A in 2025?
Ash Shehata: I think a lot of things. This year, it’s really about smart diligence. At the end of the day, there’s a lot of capabilities that we think are going to be driving that. Commercial success (operational and financial) and tax are driving a lot of the trends we’re seeing. There’s also some bigger groundwork underway for the healthcare and life sciences industry around global innovation, fueled by the future of AI.
Clearly there’s an impact right now on the financial markets due to inflation lowering. That’s going to drive deal...
Today's Sponsors
Today's Sponsor